Comprehensive narrative review explains the renaming and clinical implications of PMOS in women globally, highlighting significance.
Background: PCOS affects 1 in 8 women worldwide (170 million). In May 2026, PCOS was officially renamed to PMOS (Polyendocrine Metabolic Ovarian Syndrome) as per Lancet May 12, Johns Hopkins Medicine (Effective May 2026), NICE Guidance June 2026, RANZCOG May 13, 2026. This review by B Pharma 2nd Year student Deepak Bansal explains pathophysiology, rationale for renaming, clinical significance with high-quality flowcharts.
No takes yet. Share an insight, caveat, or question.
Deepak Bansal (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: